Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers

BACKGROUND: HER2 mutation has been found to be an oncogenic driver gene in non-small cell lung cancers(NSCLC) and HER2-directed therapies have shown promising results in this unique population, while little is known about its association with outcomes of chemotherapy. The aim of this study was to in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Cancer
Egile Nagusiak: Wang, Yan, Zhang, Shijia, Wu, Fengying, Zhao, Jing, Li, Xuefei, Zhao, Chao, Ren, Shengxiang, Zhou, Caicun
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2018
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5869778/
https://ncbi.nlm.nih.gov/pubmed/29587667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4277-x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak